Anti-platelet therapy algorithms in women

The review is focussed on the evidence base for anti-platelet therapy (APT) algorithms in women. Gender-specific features of haemostasis and thrombosis pathogenesis are emphasized. The “female” risk factors for thrombotic events include oral contraceptive use, pregnancy and post-labour period, menop...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	O. N. Tkacheva [verfasserIn] T. V. Kirsanova [verfasserIn] N. V. Latysheva [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2011

Schlagwörter:	сердечно-сосудистые заболевания тромбозы антиагрегантная терапия ацетилсалициловая кислота преэклампсия антифосфолипидный синдром

Übergeordnetes Werk:	In: Кардиоваскулярная терапия и профилактика - «SILICEA-POLIGRAF» LLC, 2019, 10(2011), 1, Seite 110-119
Übergeordnetes Werk:	volume:10 ; year:2011 ; number:1 ; pages:110-119

Links:	Link aufrufen Link aufrufen Journal toc Journal toc

Katalog-ID:	DOAJ024102237

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ024102237
003	DE-627
005	20230410104739.0
007	cr uuu---uuuuu
008	230226s2011 xx \|\|\|\|\|o 00\| \|\|rus c
035			\|a (DE-627)DOAJ024102237
035			\|a (DE-599)DOAJ462e36f86de8447c8156f802eb9728ec
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RC666-701
100	0		\|a O. N. Tkacheva \|e verfasserin \|4 aut
245	1	0	\|a Anti-platelet therapy algorithms in women
264		1	\|c 2011
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The review is focussed on the evidence base for anti-platelet therapy (APT) algorithms in women. Gender-specific features of haemostasis and thrombosis pathogenesis are emphasized. The “female” risk factors for thrombotic events include oral contraceptive use, pregnancy and post-labour period, menopause, and hormone replacement therapy. The APT role in primary and secondary cardiovascular prevention among women is analyzed. The gender-specific indications for acetylsalicylic acid therapy include pre-eclampsia, antiphospholipid syndrome, and migraine.
650		4	\|a сердечно-сосудистые заболевания
650		4	\|a тромбозы
650		4	\|a антиагрегантная терапия
650		4	\|a ацетилсалициловая кислота
650		4	\|a преэклампсия
650		4	\|a антифосфолипидный синдром
653		0	\|a Diseases of the circulatory (Cardiovascular) system
700	0		\|a T. V. Kirsanova \|e verfasserin \|4 aut
700	0		\|a N. V. Latysheva \|e verfasserin \|4 aut
773	0	8	\|i In \|t Кардиоваскулярная терапия и профилактика \|d «SILICEA-POLIGRAF» LLC, 2019 \|g 10(2011), 1, Seite 110-119 \|w (DE-627)1725534363 \|x 26190125 \|7 nnns
773	1	8	\|g volume:10 \|g year:2011 \|g number:1 \|g pages:110-119
856	4	0	\|u https://doaj.org/article/462e36f86de8447c8156f802eb9728ec \|z kostenfrei
856	4	0	\|u https://cardiovascular.elpub.ru/jour/article/view/1496 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1728-8800 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2619-0125 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 10 \|j 2011 \|e 1 \|h 110-119

Indexfelder

author_variant	o n t ont t v k tvk n v l nvl
matchkey_str	article:26190125:2011----::niltlthrpagrt
hierarchy_sort_str	2011
callnumber-subject-code	RC
publishDate	2011
allfields	(DE-627)DOAJ024102237 (DE-599)DOAJ462e36f86de8447c8156f802eb9728ec DE-627 ger DE-627 rakwb rus RC666-701 O. N. Tkacheva verfasserin aut Anti-platelet therapy algorithms in women 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The review is focussed on the evidence base for anti-platelet therapy (APT) algorithms in women. Gender-specific features of haemostasis and thrombosis pathogenesis are emphasized. The “female” risk factors for thrombotic events include oral contraceptive use, pregnancy and post-labour period, menopause, and hormone replacement therapy. The APT role in primary and secondary cardiovascular prevention among women is analyzed. The gender-specific indications for acetylsalicylic acid therapy include pre-eclampsia, antiphospholipid syndrome, and migraine. сердечно-сосудистые заболевания тромбозы антиагрегантная терапия ацетилсалициловая кислота преэклампсия антифосфолипидный синдром Diseases of the circulatory (Cardiovascular) system T. V. Kirsanova verfasserin aut N. V. Latysheva verfasserin aut In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 10(2011), 1, Seite 110-119 (DE-627)1725534363 26190125 nnns volume:10 year:2011 number:1 pages:110-119 https://doaj.org/article/462e36f86de8447c8156f802eb9728ec kostenfrei https://cardiovascular.elpub.ru/jour/article/view/1496 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2011 1 110-119
spelling	(DE-627)DOAJ024102237 (DE-599)DOAJ462e36f86de8447c8156f802eb9728ec DE-627 ger DE-627 rakwb rus RC666-701 O. N. Tkacheva verfasserin aut Anti-platelet therapy algorithms in women 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The review is focussed on the evidence base for anti-platelet therapy (APT) algorithms in women. Gender-specific features of haemostasis and thrombosis pathogenesis are emphasized. The “female” risk factors for thrombotic events include oral contraceptive use, pregnancy and post-labour period, menopause, and hormone replacement therapy. The APT role in primary and secondary cardiovascular prevention among women is analyzed. The gender-specific indications for acetylsalicylic acid therapy include pre-eclampsia, antiphospholipid syndrome, and migraine. сердечно-сосудистые заболевания тромбозы антиагрегантная терапия ацетилсалициловая кислота преэклампсия антифосфолипидный синдром Diseases of the circulatory (Cardiovascular) system T. V. Kirsanova verfasserin aut N. V. Latysheva verfasserin aut In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 10(2011), 1, Seite 110-119 (DE-627)1725534363 26190125 nnns volume:10 year:2011 number:1 pages:110-119 https://doaj.org/article/462e36f86de8447c8156f802eb9728ec kostenfrei https://cardiovascular.elpub.ru/jour/article/view/1496 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2011 1 110-119
allfields_unstemmed	(DE-627)DOAJ024102237 (DE-599)DOAJ462e36f86de8447c8156f802eb9728ec DE-627 ger DE-627 rakwb rus RC666-701 O. N. Tkacheva verfasserin aut Anti-platelet therapy algorithms in women 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The review is focussed on the evidence base for anti-platelet therapy (APT) algorithms in women. Gender-specific features of haemostasis and thrombosis pathogenesis are emphasized. The “female” risk factors for thrombotic events include oral contraceptive use, pregnancy and post-labour period, menopause, and hormone replacement therapy. The APT role in primary and secondary cardiovascular prevention among women is analyzed. The gender-specific indications for acetylsalicylic acid therapy include pre-eclampsia, antiphospholipid syndrome, and migraine. сердечно-сосудистые заболевания тромбозы антиагрегантная терапия ацетилсалициловая кислота преэклампсия антифосфолипидный синдром Diseases of the circulatory (Cardiovascular) system T. V. Kirsanova verfasserin aut N. V. Latysheva verfasserin aut In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 10(2011), 1, Seite 110-119 (DE-627)1725534363 26190125 nnns volume:10 year:2011 number:1 pages:110-119 https://doaj.org/article/462e36f86de8447c8156f802eb9728ec kostenfrei https://cardiovascular.elpub.ru/jour/article/view/1496 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2011 1 110-119
allfieldsGer	(DE-627)DOAJ024102237 (DE-599)DOAJ462e36f86de8447c8156f802eb9728ec DE-627 ger DE-627 rakwb rus RC666-701 O. N. Tkacheva verfasserin aut Anti-platelet therapy algorithms in women 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The review is focussed on the evidence base for anti-platelet therapy (APT) algorithms in women. Gender-specific features of haemostasis and thrombosis pathogenesis are emphasized. The “female” risk factors for thrombotic events include oral contraceptive use, pregnancy and post-labour period, menopause, and hormone replacement therapy. The APT role in primary and secondary cardiovascular prevention among women is analyzed. The gender-specific indications for acetylsalicylic acid therapy include pre-eclampsia, antiphospholipid syndrome, and migraine. сердечно-сосудистые заболевания тромбозы антиагрегантная терапия ацетилсалициловая кислота преэклампсия антифосфолипидный синдром Diseases of the circulatory (Cardiovascular) system T. V. Kirsanova verfasserin aut N. V. Latysheva verfasserin aut In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 10(2011), 1, Seite 110-119 (DE-627)1725534363 26190125 nnns volume:10 year:2011 number:1 pages:110-119 https://doaj.org/article/462e36f86de8447c8156f802eb9728ec kostenfrei https://cardiovascular.elpub.ru/jour/article/view/1496 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2011 1 110-119
allfieldsSound	(DE-627)DOAJ024102237 (DE-599)DOAJ462e36f86de8447c8156f802eb9728ec DE-627 ger DE-627 rakwb rus RC666-701 O. N. Tkacheva verfasserin aut Anti-platelet therapy algorithms in women 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The review is focussed on the evidence base for anti-platelet therapy (APT) algorithms in women. Gender-specific features of haemostasis and thrombosis pathogenesis are emphasized. The “female” risk factors for thrombotic events include oral contraceptive use, pregnancy and post-labour period, menopause, and hormone replacement therapy. The APT role in primary and secondary cardiovascular prevention among women is analyzed. The gender-specific indications for acetylsalicylic acid therapy include pre-eclampsia, antiphospholipid syndrome, and migraine. сердечно-сосудистые заболевания тромбозы антиагрегантная терапия ацетилсалициловая кислота преэклампсия антифосфолипидный синдром Diseases of the circulatory (Cardiovascular) system T. V. Kirsanova verfasserin aut N. V. Latysheva verfasserin aut In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 10(2011), 1, Seite 110-119 (DE-627)1725534363 26190125 nnns volume:10 year:2011 number:1 pages:110-119 https://doaj.org/article/462e36f86de8447c8156f802eb9728ec kostenfrei https://cardiovascular.elpub.ru/jour/article/view/1496 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2011 1 110-119
language	Russian
source	In Кардиоваскулярная терапия и профилактика 10(2011), 1, Seite 110-119 volume:10 year:2011 number:1 pages:110-119
sourceStr	In Кардиоваскулярная терапия и профилактика 10(2011), 1, Seite 110-119 volume:10 year:2011 number:1 pages:110-119
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	сердечно-сосудистые заболевания тромбозы антиагрегантная терапия ацетилсалициловая кислота преэклампсия антифосфолипидный синдром Diseases of the circulatory (Cardiovascular) system
isfreeaccess_bool	true
container_title	Кардиоваскулярная терапия и профилактика
authorswithroles_txt_mv	O. N. Tkacheva @@aut@@ T. V. Kirsanova @@aut@@ N. V. Latysheva @@aut@@
publishDateDaySort_date	2011-01-01T00:00:00Z
hierarchy_top_id	1725534363
id	DOAJ024102237
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ024102237</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410104739.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2011 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ024102237</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ462e36f86de8447c8156f802eb9728ec</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">O. N. Tkacheva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anti-platelet therapy algorithms in women</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The review is focussed on the evidence base for anti-platelet therapy (APT) algorithms in women. Gender-specific features of haemostasis and thrombosis pathogenesis are emphasized. The “female” risk factors for thrombotic events include oral contraceptive use, pregnancy and post-labour period, menopause, and hormone replacement therapy. The APT role in primary and secondary cardiovascular prevention among women is analyzed. The gender-specific indications for acetylsalicylic acid therapy include pre-eclampsia, antiphospholipid syndrome, and migraine.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">сердечно-сосудистые заболевания</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">тромбозы</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">антиагрегантная терапия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ацетилсалициловая кислота</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">преэклампсия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">антифосфолипидный синдром</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. V. Kirsanova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. V. Latysheva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Кардиоваскулярная терапия и профилактика</subfield><subfield code="d">«SILICEA-POLIGRAF» LLC, 2019</subfield><subfield code="g">10(2011), 1, Seite 110-119</subfield><subfield code="w">(DE-627)1725534363</subfield><subfield code="x">26190125</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:110-119</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/462e36f86de8447c8156f802eb9728ec</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://cardiovascular.elpub.ru/jour/article/view/1496</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1728-8800</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2619-0125</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2011</subfield><subfield code="e">1</subfield><subfield code="h">110-119</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	O. N. Tkacheva
spellingShingle	O. N. Tkacheva misc RC666-701 misc сердечно-сосудистые заболевания misc тромбозы misc антиагрегантная терапия misc ацетилсалициловая кислота misc преэклампсия misc антифосфолипидный синдром misc Diseases of the circulatory (Cardiovascular) system Anti-platelet therapy algorithms in women
authorStr	O. N. Tkacheva
ppnlink_with_tag_str_mv	@@773@@(DE-627)1725534363
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC666-701
illustrated	Not Illustrated
issn	26190125
topic_title	RC666-701 Anti-platelet therapy algorithms in women сердечно-сосудистые заболевания тромбозы антиагрегантная терапия ацетилсалициловая кислота преэклампсия антифосфолипидный синдром
topic	misc RC666-701 misc сердечно-сосудистые заболевания misc тромбозы misc антиагрегантная терапия misc ацетилсалициловая кислота misc преэклампсия misc антифосфолипидный синдром misc Diseases of the circulatory (Cardiovascular) system
topic_unstemmed	misc RC666-701 misc сердечно-сосудистые заболевания misc тромбозы misc антиагрегантная терапия misc ацетилсалициловая кислота misc преэклампсия misc антифосфолипидный синдром misc Diseases of the circulatory (Cardiovascular) system
topic_browse	misc RC666-701 misc сердечно-сосудистые заболевания misc тромбозы misc антиагрегантная терапия misc ацетилсалициловая кислота misc преэклампсия misc антифосфолипидный синдром misc Diseases of the circulatory (Cardiovascular) system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Кардиоваскулярная терапия и профилактика
hierarchy_parent_id	1725534363
hierarchy_top_title	Кардиоваскулярная терапия и профилактика
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1725534363
title	Anti-platelet therapy algorithms in women
ctrlnum	(DE-627)DOAJ024102237 (DE-599)DOAJ462e36f86de8447c8156f802eb9728ec
title_full	Anti-platelet therapy algorithms in women
author_sort	O. N. Tkacheva
journal	Кардиоваскулярная терапия и профилактика
journalStr	Кардиоваскулярная терапия и профилактика
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2011
contenttype_str_mv	txt
container_start_page	110
author_browse	O. N. Tkacheva T. V. Kirsanova N. V. Latysheva
container_volume	10
class	RC666-701
format_se	Elektronische Aufsätze
author-letter	O. N. Tkacheva
author2-role	verfasserin
title_sort	anti-platelet therapy algorithms in women
callnumber	RC666-701
title_auth	Anti-platelet therapy algorithms in women
abstract	The review is focussed on the evidence base for anti-platelet therapy (APT) algorithms in women. Gender-specific features of haemostasis and thrombosis pathogenesis are emphasized. The “female” risk factors for thrombotic events include oral contraceptive use, pregnancy and post-labour period, menopause, and hormone replacement therapy. The APT role in primary and secondary cardiovascular prevention among women is analyzed. The gender-specific indications for acetylsalicylic acid therapy include pre-eclampsia, antiphospholipid syndrome, and migraine.
abstractGer	The review is focussed on the evidence base for anti-platelet therapy (APT) algorithms in women. Gender-specific features of haemostasis and thrombosis pathogenesis are emphasized. The “female” risk factors for thrombotic events include oral contraceptive use, pregnancy and post-labour period, menopause, and hormone replacement therapy. The APT role in primary and secondary cardiovascular prevention among women is analyzed. The gender-specific indications for acetylsalicylic acid therapy include pre-eclampsia, antiphospholipid syndrome, and migraine.
abstract_unstemmed	The review is focussed on the evidence base for anti-platelet therapy (APT) algorithms in women. Gender-specific features of haemostasis and thrombosis pathogenesis are emphasized. The “female” risk factors for thrombotic events include oral contraceptive use, pregnancy and post-labour period, menopause, and hormone replacement therapy. The APT role in primary and secondary cardiovascular prevention among women is analyzed. The gender-specific indications for acetylsalicylic acid therapy include pre-eclampsia, antiphospholipid syndrome, and migraine.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Anti-platelet therapy algorithms in women
url	https://doaj.org/article/462e36f86de8447c8156f802eb9728ec https://cardiovascular.elpub.ru/jour/article/view/1496 https://doaj.org/toc/1728-8800 https://doaj.org/toc/2619-0125
remote_bool	true
author2	T. V. Kirsanova N. V. Latysheva
author2Str	T. V. Kirsanova N. V. Latysheva
ppnlink	1725534363
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC666-701
up_date	2024-07-03T21:12:36.226Z
_version_	1803593875432931328
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ024102237</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410104739.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2011 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ024102237</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ462e36f86de8447c8156f802eb9728ec</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">O. N. Tkacheva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anti-platelet therapy algorithms in women</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The review is focussed on the evidence base for anti-platelet therapy (APT) algorithms in women. Gender-specific features of haemostasis and thrombosis pathogenesis are emphasized. The “female” risk factors for thrombotic events include oral contraceptive use, pregnancy and post-labour period, menopause, and hormone replacement therapy. The APT role in primary and secondary cardiovascular prevention among women is analyzed. The gender-specific indications for acetylsalicylic acid therapy include pre-eclampsia, antiphospholipid syndrome, and migraine.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">сердечно-сосудистые заболевания</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">тромбозы</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">антиагрегантная терапия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ацетилсалициловая кислота</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">преэклампсия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">антифосфолипидный синдром</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. V. Kirsanova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">N. V. Latysheva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Кардиоваскулярная терапия и профилактика</subfield><subfield code="d">«SILICEA-POLIGRAF» LLC, 2019</subfield><subfield code="g">10(2011), 1, Seite 110-119</subfield><subfield code="w">(DE-627)1725534363</subfield><subfield code="x">26190125</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:110-119</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/462e36f86de8447c8156f802eb9728ec</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://cardiovascular.elpub.ru/jour/article/view/1496</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1728-8800</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2619-0125</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2011</subfield><subfield code="e">1</subfield><subfield code="h">110-119</subfield></datafield></record></collection>
score	7.401613

Nicht das Richtige dabei?

Schreiben Sie uns!

Anti-platelet therapy algorithms in women

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?